ramucirumab功能化磁脂质体靶向递送索拉非尼和MRI的治疗潜力。

IF 3.9 3区 医学 Q2 CHEMISTRY, MEDICINAL
Journal of pharmaceutical sciences Pub Date : 2026-09-01 Epub Date: 2026-06-24 DOI:10.1016/j.xphs.2026.104402
Ali Pouresmaeili, Abolghasem Abbasi Kajani
{"title":"ramucirumab功能化磁脂质体靶向递送索拉非尼和MRI的治疗潜力。","authors":"Ali Pouresmaeili,&nbsp;Abolghasem Abbasi Kajani","doi":"10.1016/j.xphs.2026.104402","DOIUrl":null,"url":null,"abstract":"<div><div>Development of theranostic nanoplatforms capable of the controlled and targeted delivery of anticancer agents and simultaneous bioimaging has attracted great attention as an exciting and frontier research field. Here, the sorafenib loaded magnetoliposomes (S-MLPs) were synthesized and targeted individually, with a specific aptamer (AS-MLPs) and the ramucirumab antibody (RS-MLPs) against the vascular endothelial growth factor receptor 2 (VEGFR2). The physicochemical characterization revealed the synthesis of high colloidal and monodisperse S-MLPs with an average hydrodynamic size of 147 nm and a zeta potential value of -26.4 mV. The <em>in vitro</em> release study showed a linear release profile for sorafenib with 66.47% cumulative release during 96 h. The anticancer activity of S-MLPs was studied <em>in vitro</em> using the MTT assay, flow cytometry study of apoptosis and necrosis, and the gene expression analysis using real-time PCR and ELISA. The theranostic potential of S-MLPs was also confirmed by the MRI and CAM assay, <em>in vivo</em>. The results demonstrated the lowest cell viabilities of 69.54 and 54.19% after exposure of HepG2 cells to 100 μg mL<sup>−1</sup> of AS-MLPs and RS-MLPs, respectively. Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL<sup>−1</sup>. The R2 relaxation value of 57.262 mM<sup>−1</sup> s<sup>−1</sup> obtained for the MLPs, indicating their high potential for clinical cancer management.</div></div>","PeriodicalId":16741,"journal":{"name":"Journal of pharmaceutical sciences","volume":"115 9","pages":"Article 104402"},"PeriodicalIF":3.9000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI\",\"authors\":\"Ali Pouresmaeili,&nbsp;Abolghasem Abbasi Kajani\",\"doi\":\"10.1016/j.xphs.2026.104402\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Development of theranostic nanoplatforms capable of the controlled and targeted delivery of anticancer agents and simultaneous bioimaging has attracted great attention as an exciting and frontier research field. Here, the sorafenib loaded magnetoliposomes (S-MLPs) were synthesized and targeted individually, with a specific aptamer (AS-MLPs) and the ramucirumab antibody (RS-MLPs) against the vascular endothelial growth factor receptor 2 (VEGFR2). The physicochemical characterization revealed the synthesis of high colloidal and monodisperse S-MLPs with an average hydrodynamic size of 147 nm and a zeta potential value of -26.4 mV. The <em>in vitro</em> release study showed a linear release profile for sorafenib with 66.47% cumulative release during 96 h. The anticancer activity of S-MLPs was studied <em>in vitro</em> using the MTT assay, flow cytometry study of apoptosis and necrosis, and the gene expression analysis using real-time PCR and ELISA. The theranostic potential of S-MLPs was also confirmed by the MRI and CAM assay, <em>in vivo</em>. The results demonstrated the lowest cell viabilities of 69.54 and 54.19% after exposure of HepG2 cells to 100 μg mL<sup>−1</sup> of AS-MLPs and RS-MLPs, respectively. Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL<sup>−1</sup>. The R2 relaxation value of 57.262 mM<sup>−1</sup> s<sup>−1</sup> obtained for the MLPs, indicating their high potential for clinical cancer management.</div></div>\",\"PeriodicalId\":16741,\"journal\":{\"name\":\"Journal of pharmaceutical sciences\",\"volume\":\"115 9\",\"pages\":\"Article 104402\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2026-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmaceutical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022354926002510\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/6/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022354926002510","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

作为一个令人兴奋的前沿研究领域,能够控制和靶向递送抗癌药物并同时进行生物成像的治疗纳米平台的发展受到了广泛关注。在这里,我们合成了负载索拉非尼的磁脂质体(S-MLPs)并单独靶向,具有特异性适配体(AS-MLPs)和抗血管内皮生长因子受体2 (VEGFR2)的ramucirumab抗体(RS-MLPs)。理化表征表明,合成的高胶体单分散S-MLPs平均水动力尺寸为147 nm, zeta电位值为-26.4 mV。体外释放研究显示,索拉非尼体外释放呈线性,96 h累积释放量为66.47%。采用MTT法、细胞凋亡和坏死的流式细胞术研究以及实时荧光定量PCR和酶联免疫吸附法分析S-MLPs的体外抗癌活性。S-MLPs的治疗潜力也通过MRI和CAM实验在体内得到证实。结果表明,100 μg mL-1的AS-MLPs和RS-MLPs作用于HepG2细胞后,细胞存活率最低,分别为69.54%和54.19%。此外,用S-MLPs处理HepG2细胞导致凋亡蛋白活性增加12.99倍,血管生成蛋白的产生从331.57 pg mL-1减少到83.34 pg mL-1。mlp的R2松弛值为57.262 mM-1 s-1,表明其具有很高的临床肿瘤治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI

Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI
Development of theranostic nanoplatforms capable of the controlled and targeted delivery of anticancer agents and simultaneous bioimaging has attracted great attention as an exciting and frontier research field. Here, the sorafenib loaded magnetoliposomes (S-MLPs) were synthesized and targeted individually, with a specific aptamer (AS-MLPs) and the ramucirumab antibody (RS-MLPs) against the vascular endothelial growth factor receptor 2 (VEGFR2). The physicochemical characterization revealed the synthesis of high colloidal and monodisperse S-MLPs with an average hydrodynamic size of 147 nm and a zeta potential value of -26.4 mV. The in vitro release study showed a linear release profile for sorafenib with 66.47% cumulative release during 96 h. The anticancer activity of S-MLPs was studied in vitro using the MTT assay, flow cytometry study of apoptosis and necrosis, and the gene expression analysis using real-time PCR and ELISA. The theranostic potential of S-MLPs was also confirmed by the MRI and CAM assay, in vivo. The results demonstrated the lowest cell viabilities of 69.54 and 54.19% after exposure of HepG2 cells to 100 μg mL−1 of AS-MLPs and RS-MLPs, respectively. Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL−1. The R2 relaxation value of 57.262 mM−1 s−1 obtained for the MLPs, indicating their high potential for clinical cancer management.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.30
自引率
13.20%
发文量
367
审稿时长
33 days
期刊介绍: The Journal of Pharmaceutical Sciences will publish original research papers, original research notes, invited topical reviews (including Minireviews), and editorial commentary and news. The area of focus shall be concepts in basic pharmaceutical science and such topics as chemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability of drugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书